[Lumbar myelography with metrizamid (author's transl)].
A series of lumbar myelographies -- 105 in 98 patients - was carried out with water-soluble Metrizamid (Amipaque R) in a concentration of 170 mg I/ml and showed side-effects in 32% and a quality of contrast similar to that of other water-soluble contrast media used before. The side effects were mild, of short duration and needed no treatment. There were no epileptic fits, tonic or clonic carried out 1 - 12 months later showed no signs of arachnoiditis. Dangers of more serious complications appeared to increase, the higher the level of injection into the spinal canal. A short survey of contrast media used in myelography and earlier experience of experimental or clinical side effects caused by Medtrizamid in myelography follows.
D000328:Adult; D000368:Aged; D003287:Contrast Media; D005260:Female; D006801:Humans; D007463:Iodobenzoates; D008161:Lumbosacral Region; D008297:Male; D008793:Metrizamide / Q000009:adverse effects; D008875:Middle Aged; D009192:Myelography / Q000009:adverse effects / Q000379:methods*
D003287:Contrast Media; D007463:Iodobenzoates; D008793:Metrizamide
Lumbale Myelographie mit Medtizamid